FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Mager

Research Profile

Concepts & Ideas

Living Beings

Rats

Phenomena

Occupations

Activities & Behaviors

Statistics

Physiology

Avoidance Learning

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Kerstin Wirkner; Doychin Stanchev; Doreen Milius; Lars Hartmann; Erzsebet Kato; Zoltan S Zadori; Peter P Mager; Patrizia Rubini; Wolfgang Nörenberg; Peter Illes
Regulation of the pH sensitivity of human P2X receptors by N-linked glycosylation.
Wolfgang Fischer; Zoltan S Zadori; Yvonne Kullnick; Helke Gröger-Arndt; Heike Franke; Kerstin Wirkner; Peter Illes; Peter P Mager
Conserved lysin and arginin residues in the extracellular loop of P2X(3) receptors are involved in agonist binding.
Peter P Mager; Peter Illes
The h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Mager (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Kerstin Wirkner; Doychin Stanchev; Doreen Milius; Lars Hartmann; Erzsebet Kato; Zoltan S Zadori; Peter P Mager; Patrizia Rubini; Wolfgang Nörenberg; Peter Illes
Regulation of the pH sensitivity of human P2X receptors by N-linked glycosylation.
Journal of neurochemistry 2008;107(5):1216-24.
2007: Wolfgang Fischer; Zoltan S Zadori; Yvonne Kullnick; Helke Gröger-Arndt; Heike Franke; Kerstin Wirkner; Peter Illes; Peter P Mager
Conserved lysin and arginin residues in the extracellular loop of P2X(3) receptors are involved in agonist binding.
European journal of pharmacology 2007;576(1-3):7-17.
2006: Peter P Mager; Peter Illes
The h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.
Expert opinion on drug discovery 2006;1(4):303-9.
2006: Peter P Mager; Anje Weber; Luis Sanchez; Kerstin Wirkner; Peter Illes
The monomers of the P2X1 receptor model and KcsA protein share a similar structural fold.
Protein and peptide letters 2006;13(1):77-81.
2005: Kerstin Wirkner; Doychin Stanchev; László Köles; Markus Klebingat; Hassan Dihazi; Gesine Flehmig; Catherine Vial; Richard J Evans; Zsuzsanna Fürst; Peter P Mager; Klaus Eschrich; Peter Illes
Regulation of human recombinant P2X3 receptors by ecto-protein kinase C.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(34):7734-42.
2005: Peter P Mager; Anje Weber; Peter Illes
Quantitative structure-activity relationship analysis of the cation permeability of the P2X2 channel.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2005;1(2):109-15.
2004: Paul Berghuis; Marton B Dobszay; Kyle M Sousa; Gunnar Schulte; Peter P Mager; Wolfgang Härtig; Tamás J Görcs; Yuri Zilberter; Patrik Ernfors; Tibor Harkany
Brain-derived neurotrophic factor controls functional differentiation and microcircuit formation of selectively isolated fast-spiking GABAergic interneurons.
The European journal of neuroscience 2004;20(5):1290-306.
2004: Peter P Mager; Anje Weber; Peter Illes
Bridging the gap between structural bioinformatics and receptor research: the membrane-embedded, ligand-gated, P2X glycoprotein receptor.
Current topics in medicinal chemistry 2004;4(16):1657-705.
2003: Peter P Mager
Hybrid canonical-correlation neural-network approach applied to nonnucleoside HIV-1 reverse transcriptase inhibitors (HEPT derivatives).
Current medicinal chemistry 2003;10(17):1643-59.
2003: Peter P Mager; Anje Weber
Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes.
Drug design and discovery 2003;18(4):127-50.
2003: Peter P Mager; Erik De Clercq; Matheus Froeyen; R Reinhardt
Interactions of the dimeric triad of HIV-1 aspartyl protease with inhibitors.
Drug design and discovery 2003;18(2-3):53-64.
2001: Peter P Mager
The active site of HIV-1 protease.
Medicinal research reviews 2001;21(4):348-53.
1999: Peter P Mager; R Reinhardt
A comparison of backpropagation and generalized-regression genetic-neural network models.
Drug design and discovery 1999;16(1):49-53.
1998: Peter P Mager
Molecular simulation of the primary and secondary structures of the Abeta(1-42)-peptide of Alzheimer's disease.
Medicinal research reviews 1998;18(6):403-30.
1997: Peter P Mager
The role of diagnostic statistics in medicinal chemistry.
Medicinal research reviews 1997;17(6):505-22.
1997: Peter P Mager
How design statistics concepts can improve experimentation in medicinal chemistry.
Medicinal research reviews 1997;17(5):453-75.
1997: Peter P Mager
A check on rational drug design: molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase.
Medicinal research reviews 1997;17(3):235-76.
1996: Peter P Mager
Evidence of a butterfly-like configuration of structurally diverse allosteric inhibitors of the HIV-1 reverse transcriptase.
Drug design and discovery 1996;14(3):241-57.
1996: Peter P Mager; H Walther
A hydrophilic omega-loop (Tyr181 to Tyr188) in the nonsubstrate binding area of HIV-1 reverse transcriptase.
Drug design and discovery 1996;14(3):225-39.
1996: Peter P Mager
Molecular simulation of the folding patterns of the omega-loop (Tyr181 to Tyr188) of HIV-1 reverse transcriptase.
Drug design and discovery 1996;14(3):213-23.
1996: R Reinhardt; M Richter; Peter P Mager
Investigation of the conformational behaviour of permethylated cyclodextrins by molecular modelling.
Carbohydrate research 1996;291():1-9.
1995: Peter P Mager; R Reinhardt; M Richter; H Walther; B Rockel
Molecular simulation of 8-styrylxanthines.
Drug design and discovery 1995;13(2):89-107.
1994: Peter P Mager
Non-least-squares regression analysis applied to organic and medicinal chemistry.
Medicinal research reviews 1994;14(5):533-88.
1994: Peter P Mager
Interactive multivariate modelling of 4-amino-2-carboxytetrahydroquinolines as antagonists of the glycine-site directed NMDA receptor-ion channel complex.
Drug design and discovery 1994;11(3):185-96.
1994: Peter P Mager
Interactive multivariate modeling of ArgGlyAsp (RGD) derivatives.
Medicinal research reviews 1994;14(1):75-126.
1993: Peter P Mager; H Mager; H Walther
QSAR and molecular modelling of antimuscarinic 7-amino-1-hydroxy-5-heptyn-2-ones.
Drug design and discovery 1993;10(2):135-56.
1993: Peter P Mager
Interactive multivariate analysis of bisindolylmaleimides as potent protein kinase C antagonists.
Drug design and discovery 1993;10(3):231-48.
1992: Peter P Mager; R A Coburn; A J Solo; D J Triggle; H Rothe
QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead.
Drug design and discovery 1992;8(4):273-89.
1992: Peter P Mager
QSAR, diagnostic statistics, and molecular modelling of antiallergic acrylamide derivatives.
Drug design and discovery 1992;9(2):107-18.
1991: Peter P Mager
Computer-assisted series design in chemical synthesis of bioactive compounds.
Medicinal research reviews 1991;11(4):375-402.
1991: Peter P Mager
Nonleast-squares jackknife regression in drug design.
Drug design and delivery 1991;7(2):119-29.
1991: Peter P Mager
Linear free energy-related and quantitative structure-activity relationships of inhibitors of thymidylate synthetase.
Drug design and delivery 1991;7(3):203-18.
1990: Peter P Mager; H Rothe
Obscure phenomena in statistical analysis of quantitative structure-activity relationships. Part 1: Multicollinearity of physicochemical descriptors.
Die Pharmazie 1990;45(10):758-64.
1990: Peter P Mager; H Rothe
Regression estimation from grouped observations applied to structurally diverse D2-receptor antagonists.
Die Pharmazie 1990;45(6):424-33.
1990: Peter P Mager
Reduced Free-Wilson approach applied to HSV-1 antiviral 7-amino-quinolines.
Die Pharmazie 1990;45(5):359-60.
1989: R Mager; Peter P Mager; W Ullrich; B Enzenross; D Mücke
[New non-invasive possibilities for assessing the function of the utero- and fetoplacental unit: Doppler sonography flow characteristics of selected arteries in normal pregnancy].
Pädiatrie und Grenzgebiete 1989;28(3):131-8.
1989: F Klingberg; Peter P Mager; R Mager
The mesencephalic reticular formation as a link in the cortical control of exploratory and goal-directed behaviour.
Acta physiologica Hungarica 1989;74(2):121-34.
1988: Peter P Mager
[The optimization of bioactive lead structures. III. Verification of the system].
Pharmazie in unserer Zeit 1988;17(6):177-88.
1988: Peter P Mager
[Optimization of the bioactive lead structure. II. Verification of the system].
Pharmazie in unserer Zeit 1988;17(5):129-44.
1988: Peter P Mager
[The optimization of bioactive lead structure I. Test of the system].
Pharmazie in unserer Zeit 1988;17(4):106-26.
1987: Peter P Mager
[The development of bioactive structures. Systems testing].
Pharmazie in unserer Zeit 1987;16(4):97-121.
1987: Anita Seese; Peter P Mager
[Simple bimolecular reaction model with physical feedback mechanism in the handling of rhythmic processes and their modification of receptor populations].
Gegenbaurs morphologisches Jahrbuch 1987;133(4):581-603.
1986: Peter P Mager; R Mager; F Klingberg
The pretectal region of the rat participates in the regulation of goal-directed behaviour.
Biomedica biochimica acta 1986;45(4):477-83.
1986: Peter P Mager; R Mager; F Klingberg
The effect of lesions in the mesencephalic reticular formation upon conditioned avoidance responses in rat. III. Lesions of the area subcuneiformis.
Biomedica biochimica acta 1986;45(3):385-92.
1984: Peter P Mager
[Unity through diversity: the use of multivariate methods in drug research].
Pharmazie in unserer Zeit 1984;13(5):147-55.
1984: Peter P Mager; R Mager; F Klingberg
The effect of lesions in the mesencephalic reticular formation upon conditioned avoidance responses in rat: I. Lesions of the nucleus commissurae posterioris.
Biomedica biochimica acta 1984;43(1):85-93.
1984: Peter P Mager
[Concepts of synthesis in drug research].
Pharmazie in unserer Zeit 1984;13(1):1-12.
1984: Peter P Mager; R Mager; F Klingberg
The effect of lesions in the mesencephalic reticular formation upon conditioned avoidance responses in rat. II. Lesions of the area cuneiformis.
Biomedica biochimica acta 1984;43(10):1145-55.
1983: Peter P Mager
Theoretical approaches to drug design and biological activity: II. Multivariate structure-activity relationships in combination with the multivariate bioassay (MASCA model).
Medicinal research reviews 1983;3(4):435-98.
1983: Peter P Mager
Structure-activity relationships of dermorphin tetrapeptide amides.
Die Pharmazie 1983;38(8):563.
1983: H G Schauzu; Peter P Mager
A free-wilson study of 4-piperazinyl-10h-thienobenzodiazepine analogues.
Die Pharmazie 1983;38(8):562.
1983: Peter P Mager
QSAR applied to aging of phosphylated acetylcholinesterase.
Die Pharmazie 1983;38(4):271-2.
1983: Peter P Mager
Inverse structure-activity relationships.
Die Pharmazie 1983;38(3):194-5.
1983: Peter P Mager
Indirect discrimination of type 1 mu and 1 delta opioid receptor properties using quantitative structure-activity relationships.
Activitas nervosa superior 1983;25(1):66-8.
1983: Peter P Mager; R Mager; F Klingberg
Open field behaviour of rats after various mesencephalic lesions.
Biomedica biochimica acta 1983;42(10):1257-67.
1982: H Mager; B Schneeweiss; A Barth; Peter P Mager
Judging models in QSAR- and LFE-like studies if there are no replications: correlation of dipeptidyl peptidase IV hydrolytic activities of L-Alanyl-L-alanine phenylamides.
Die Pharmazie 1982;37(12):856-7.
1982: Peter P Mager; S Das Gupta
Organotins: toxicity and oligomycin-like effect on mitochondria in dependence on chemical structure.
Die Pharmazie 1982;37(11):801.
1982: Peter P Mager
Quantitative structure-activity relationships of reactivators of phosphylated acetylcholinesterase. Part 3.
Die Pharmazie 1982;37(11):800-1.
1982: Peter P Mager
Multivariate response surface optimization.
Die Pharmazie 1982;37(9):658-60.
1982: Peter P Mager; S Das Gupta
Quantitative structure-activity relationships of reactivators of phosphylated acetylcholinesterase. Part 2.
Die Pharmazie 1982;37(8):607-8.
1982: Peter P Mager
Structure-neurotoxicity relationships applied to organophosphorus pesticides.
Toxicology letters 1982;11(1-2):67-71.
1982: S Schumann; G Mann; H Wilde; U Ploen; Peter P Mager
[Biological effects of 3-substituted acetic acid derivatives of 1,2,4-benzotriazines].
Die Pharmazie 1982;37(2):148-9.
1982: Peter P Mager; R Mager; F Klingberg
Visual placing responses impaired after mesencephalic lesions in the rat.
Acta biologica et medica Germanica 1982;41(10):971-5.
1982: Peter P Mager
Theoretical approaches to drug design and biological activity: critical comments to the use of mathematical methods applied to univariate and multivariate quantitative structure-activity relationships (QSAR).
Medicinal research reviews 1982;2(1):93-121.
1981: Peter P Mager; Anita Seese; H Hikino; T Ohta; M Ogura; Y Ohizumi; C Konno; T Takemoto
Quantitative structure-toxicity relationships applied to grayanotoxins.
Die Pharmazie 1981;36(10):717.
1981: Peter P Mager; Anita Seese
[Feasibility and limitations of MASCA models (multivariate structure-activity analysis in combination with multivariate bioassay].
Pharmazie in unserer Zeit 1981;10(4):97-108.
1981: Peter P Mager
Quantitative structure-reactivity and structure-toxicity relationships of reactivators of phosphylated acetylcholinesterase.
Die Pharmazie 1981;36(6):450-1.
1981: Peter P Mager
Branching in structure-toxicity relationships applied to organophosphorus pesticides of the DDVP (dichlorvos) type: a novel phenomenon in QSAR.
Die Pharmazie 1981;36(6):448-9.
1981: Peter P Mager; Anita Seese
[Multivariate Free-Wilson analysis (author's transl)].
Die Pharmazie 1981;36(6):427-9.
1981: Peter P Mager
Pattern recognition and time-dependent QSAR applied to morphinomimetic opioids.
Activitas nervosa superior 1981;23(2):136-56.
1981: Peter P Mager
Overall-response parameter analysis applied to butyrophenones.
Activitas nervosa superior 1981;23(2):130-5.
1981: Peter P Mager
Structure-toxicity relationships applied to bicyclic organophosphorus poisons.
Die Pharmazie 1981;36(5):382-3.
1981: Peter P Mager; Anita Seese; K Takeya
Structure-toxicity relationships applied to grayanotoxins.
Die Pharmazie 1981;36(5):381-2.
1981: Peter P Mager
Grouped observations in quantitative structure-toxicity relationships of organophosphorus poisons.
Die Pharmazie 1981;36(7):513-4.
1981: Peter P Mager
Response surface optimization to neurotoxic organophosphorus poisons.
Die Pharmazie 1981;36(7):511-2.
1980: Peter P Mager; H Böhm; H Wilde; G Mann
[Growth inhibition in Chlorella vulgaris by 4-substituted 3-methyl-1-phenylpyrazolin-5-one derivatives as related to their chemical structure].
Die Pharmazie 1980;35(12):807-8.
1980: Peter P Mager; Anita Seese
[Quantitative structure-toxicity relationships of phosphoric acid esters].
Die Pharmazie 1980;35(12):806-7.
1980: Peter P Mager; Anita Seese
[Quantitative structure-activity relationships between amino acids, and a contribution to hyperbolic structure-activity analysis].
Die Pharmazie 1980;35(12):805-6.
1980: Peter P Mager
[Structure-activity relationship with degree of saturation].
Die Pharmazie 1980;35(11):708-9.
1979: Peter P Mager; M Paintz; U Wenzel
[On the use of the relative surface tension xi in studies on the structure-activity relationships (author's transl)].
Die Pharmazie 1979;34(3):174-8.
1976: Peter P Mager
[MASCA-model of biochemical-pharmacological drug research/Part VIII: Examples (author's transl)].
Arzneimittel-Forschung 1976;26(2):185-7.
1976: Peter P Mager
Oscillations and cysteine metabolism in aortic strips of hypertensive rats.
Arzneimittel-Forschung 1976;26(12):2164-6.
1976: Peter P Mager
[MASCA-Model of biochemical-pharmacological drug research/part 7: Computing scheme for the MASCA-model (author's transl)].
Arzneimittel-Forschung 1976;26(1):26-8.
1976: Peter P Mager
Hysteresis at an electrochemical membrane model and its possible role in circulation research.
Arzneimittel-Forschung 1976;26(10):1818-9.
1975: Peter P Mager
[MASCA-model of the biochemical-pharmacological drug research / part 5: Structure-activity relationships and MACOVA (author's transl)].
Arzneimittel-Forschung 1975;25(11):1745.
1975: Peter P Mager
[MASCA-model of the biochemical-pharmacological drug research/ part 4: Structure-activity relationships and MANOVA (author's transl)].
Arzneimittel-Forschung 1975;25(10):1475-6.
1975: Peter P Mager
[MASCA-model of the biochemical-pharmacological drug research. Part 3: Structure-activity relationships and KANORA (author's transl)].
Arzneimittel-Forschung 1975;25(9):1355-6.
1975: Peter P Mager
A multivariate autoregressive transformation of an empirical time series which bases on the principal component analysis.
Activitas nervosa superior 1975;17(3):185-6.
1975: Peter P Mager
[MASCA-model of the biochemical-pharmacological drug research. Part 2: Multivariate test criterions and methods (author's transl)].
Arzneimittel-Forschung 1975;25(8):1270-2.
1975: Peter P Mager
[MASCA-model of the biochemical-pharmacological drug research/part 1: Principle of the univariate structure-activity relationship and definitions of physico-chemical parameters (author's transl)].
Arzneimittel-Forschung 1975;25(7):1006-8.
1975: Peter P Mager
The discrimination in time series analysis - a working procedure.
Activitas nervosa superior 1975;17(2):149-54.
1975: Peter P Mager
[MASCA-model of biochemical-pharmacological drug research. Part 6: Structure-activity relationship and bio-oscillations (author's transl)].
Arzneimittel-Forschung 1975;25(12):1864-5.
1975: Peter P Mager; R Mager
[Some remarks on the problem of variance inhomogeneity in medical data analysis (author's transl)].
Gegenbaurs morphologisches Jahrbuch 1975;121(3):340-4.
1974: Peter P Mager; F Klingberg
[Effect of intraventricular application of L-glutamic acid on the acquisition and extinction of an instrumental conditioning reaction in rats].
Experientia 1974;30(10):1189-90.
1974: Peter P Mager
Allosteric inhibition of L-glutamic acid decarboxylase by valine in rat brain.
Activitas nervosa superior 1974;16(1):19-20.
1974: Peter P Mager; R Mager
[The probability network. I. Testing for normal distribution and analysis of a mixed group].
Gegenbaurs morphologisches Jahrbuch 1974;120(4):560-74.
1974: Peter P Mager; R Mager
Life, nonequilibrium thermodynamics and autocorrelation function.
Gegenbaurs morphologisches Jahrbuch 1974;120(4):529-37.
1974: R Mager; Peter P Mager
[Probability-screening. II. Variable transformation].
Gegenbaurs morphologisches Jahrbuch 1974;120(5):620-6.
1974: Peter P Mager; R Mager
[Probability network. I. Testing on the normal distribution and analysis of a mixed collective].
Gegenbaurs morphologisches Jahrbuch 1974;120(4):560-74.
1973: Peter P Mager; F Klingberg
The effect of L-tryptophane upon the elaboration and extinction of a conditioned avoidance response and upon the behaviour of rats.
Acta biologica et medica Germanica 1973;31(6):889-92.
1972: Peter P Mager; S Theil; F Klingberg
[Influence of l(+)-cysteine and l(-)-cystine on the startle reaction of the rat in motivated and unmotivated situation].
Acta biologica et medica Germanica 1972;28(2):387-90.
1972: Peter P Mager; S Theil; F Klingberg
[The influence of L(+) cysteine and L(-) cystine on elaboration, retention, and extinction of the conditional escape reaction of rats].
Acta biologica et medica Germanica 1972;28(3):507-14.
1972: Peter P Mager; S Theil; F Klingberg
The effect of L-tyrosine and glycine upon the elaboration of a conditioned avoidance response in rats.
Acta biologica et medica Germanica 1972;29(6):933-5.
1972: Peter P Mager; S Theil; F Klingberg
[Effect of DL-methionine and DL-valine on elaboration and extinction of a conditioned avoidance reaction (avoidance conditioning)].
Acta biologica et medica Germanica 1972;28(6):1081-4.